top of page

July 26, 2021 – Tau Antisense Drug Trial: Phase 1b Results

Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. Click here to learn more.


Comentarios


bottom of page